Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory Therapy

Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory Therapy

Objective Progressive pulmonary fibrosis (PPF) is the leading cause of death in systemic sclerosis (SSc). This study aimed to develop a clinical prediction nomogram using clinical and biological data to assess risk of PPF among patients receiving treatment of SSc‐related interstitial lung disease (S...

Full description

Bibliographic Details
Main Authors:	Elizabeth R. Volkmann, Holly Wilhalme, Shervin Assassi, Grace Hyun J. Kim, Jonathan Goldin, Masataka Kuwana, Donald P. Tashkin, Michael D. Roth
Format:	Article
Language:	English
Published:	Wiley 2023-10-01
Series:	ACR Open Rheumatology
Online Access:	https://doi.org/10.1002/acr2.11598

Similar Items

Racial Disparities in Systemic Sclerosis: Short‐ and Long‐Term Outcomes Among African American Participants of SLS I and II
by: Elizabeth R. Volkmann, et al.
Published: (2021-01-01)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
by: Toby M Maher, et al.
Published: (2023-02-01)

Strategies for regulating tissue fibrosis and their clinical application
by: Masataka Kuwana
Published: (2020-04-01)

Enrichment Strategy for Systemic Sclerosis Clinical Trials Targeting Skin Fibrosis: A Prospective, Multiethnic Cohort Study
by: Carina Mihai, et al.
Published: (2020-08-01)

Symposium 3 <subtitle>Improving the Outcome of Systemic Sclerosis</subtitle>
by: Masataka KUWANA
Published: (2023-11-01)

The role of type 1 interferon in systemic sclerosis
by: Minghua eWu, et al.
Published: (2013-09-01)

Updates on genetics in systemic sclerosis
by: Yuko Ota, et al.
Published: (2021-06-01)

Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient‐Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II
by: Elizabeth R. Volkmann, et al.
Published: (2020-06-01)

Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)
by: Dinesh Khanna, et al.
Published: (2019-01-01)

Endothelial cells and endothelial progenitor cells in the pathogenesis of systemic sclerosis
by: Yuko Ota, et al.
Published: (2020-10-01)

Immunomodulatory effects of exosomes from different resources on idiopathic pulmonary fibrosis
by: Wu Jiamin, Zhang Wei, Zhang Xing, Chen Qi
Published: (2022-05-01)

Progression of Relapsing-Remitting Multiple Sclerosis despite the new era of treatments
by: Gutemberg Augusto Cruz dos Santos, et al.
Published: (2022-12-01)

The Impact of Progressive Pulmonary Fibrosis in Systemic Sclerosis–Associated Interstitial Lung Disease
by: María Martín-López, et al.
Published: (2023-10-01)

Proteomic aptamer analysis reveals serum markers that characterize preclinical systemic sclerosis (SSc) patients at risk for progression toward definite SSc
by: Chiara Bellocchi, et al.
Published: (2023-01-01)

Detection of alveolar fibrocytes in idiopathic pulmonary fibrosis and systemic sclerosis.
by: Raphael Borie, et al.
Published: (2013-01-01)

Transcriptional insights into pathogenesis of cutaneous systemic sclerosis using pathway driven meta-analysis assisted by machine learning methods.
by: Xiao Xu, et al.
Published: (2020-01-01)

Dyspnoea with progressive “idiopathic” pulmonary fibrosis
by: Chahat Puri, et al.
Published: (2021-07-01)

Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease
by: Tashkin DP
Published: (2020-11-01)

Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
by: Yuichiro Shirai, et al.
Published: (2021-10-01)

The immunomodulatory phenomenon of vitamin D in the pathogenesis of Multiple Sclerosis
by: Karolina Raksa, et al.
Published: (2023-03-01)

The use of immunomodulatory therapy in pregnant patients with multiple sclerosis
by: Julia Rudnicka-Czerwiec, et al.
Published: (2018-11-01)

Immunomodulatory role of mesenchymal stem cell therapy in liver fibrosis
by: Peng Liu, et al.
Published: (2023-01-01)

Immunomodulatory function of the cystic fibrosis modifier gene BPIFA1.
by: Aabida Saferali, et al.
Published: (2020-01-01)

454 The Role of bHLHe40 in Systemic Sclerosis-associated Pulmonary Fibrosis
by: Adegboyega "Tim" Adewale, et al.
Published: (2024-04-01)

The Immunomodulatory Potential of Short-Chain Fatty Acids in Multiple Sclerosis
by: Laura Barcutean, et al.
Published: (2024-03-01)

Proposals to improve adherence to immunomodulatory therapies in patients with multiple sclerosis
by: E. Arroyo, et al.
Published: (2010-01-01)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
by: Toby M Maher, et al.
Published: (2023-12-01)

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
by: Tashkin DP, et al.
Published: (2018-06-01)

Progressive brain tissue loss and reduction of N-acetylaspartate despite immunomodulatory therapy in relapsing-remitting multiple sclerosis: results of a longitudinal single-centre study analysing MR spectroscopic, brain volume and focal tissue changes
by: Enzinger, C, et al.
Published: (2005)

Experience With Nintedanib in Severe Pulmonary Fibrosis Associated With Systemic Sclerosis: A Case Series
by: Jaume Bordas-Martinez, et al.
Published: (2021-01-01)

Osteogenic Sarcoma in an Adolescent With Cystic Fibrosis: Successful Treatment Despite Significant Obstacles
by: Thomas J. C. Ruffles, et al.
Published: (2018-09-01)

Immunomodulatory Potential of Human Mesenchymal Stem Cells and their Exosomes on Multiple Sclerosis
by: Hussein Baharlooi, et al.
Published: (2022-03-01)

Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works
by: Amélia Mendes, et al.
Published: (2011-06-01)

Deep Learning Classification of Systemic Sclerosis Skin Using the MobileNetV2 Model
by: Metin Akay, et al.
Published: (2021-01-01)

Precapillary Pulmonary Arterial Hypertension Despite Contrary Anchoring Bias
by: Patrick Keller, MD, et al.
Published: (2023-09-01)

Both N- and C-terminal domains of galectin-9 are capable of inducing HIV reactivation despite mediating differential immunomodulatory functionalities
by: Ashwini Shete, et al.
Published: (2022-12-01)

Effect of combined pulmonary fibrosis and emphysema on patients with connective tissue diseases and systemic sclerosis: a systematic review and meta-analysis
by: Bon San Koo, et al.
Published: (2021-04-01)

Predicting the Progression of Very Early Systemic Sclerosis: Current Insights
by: Bellocchi C, et al.
Published: (2022-09-01)

The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis.
by: Nina Fransén Pettersson, et al.
Published: (2018-01-01)

Circulating cytokine levels in systemic sclerosis related interstitial lung disease and idiopathic pulmonary fibrosis
by: Boyang Zheng, et al.
Published: (2023-04-01)